Trial Profile
Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms MMM 02 Study
- 20 Aug 2021 Planned End Date changed from 1 Jun 2024 to 1 Oct 2025.
- 20 Aug 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Oct 2024.
- 20 Aug 2021 Status changed from recruiting to active, no longer recruiting.